BioXcel Therapeutics Securities Settlement
$1.10–$1.52
This settlement is closed to new claims — the deadline was June 30, 2026. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
BioXcel Therapeutics and its executives allegedly violated federal securities laws by making materially false or misleading statements and omissions regarding the company's business. Defendants deny wrongdoing and settled to avoid the costs and risks of continued litigation.
Do you qualify?
Anyone who purchased or acquired BioXcel Therapeutics, Inc. common stock (CUSIP: 09075P204) between March 9, 2023 and June 28, 2023, inclusive.
How to file
Submit a valid Proof of Claim and Release Form online or by mail postmarked on or before June 30, 2026. The form requires documentation of your securities purchases. You can file online at the settlement website or mail to Strategic Claims Services, 600 N. Jackson St., Suite 205, Media, PA 19063.
Common questions
- How much does the BioXcel Therapeutics Securities Settlement pay?
- Estimated payout: $1.10–$1.52. The total settlement fund is $9.8M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
- What is the claim deadline for the BioXcel Therapeutics Securities Settlement?
- This settlement is closed to new claims — the deadline was June 30, 2026. Once a claim deadline passes you generally forfeit your share, even if you qualified.
- Do I need proof of purchase for the BioXcel Therapeutics Securities Settlement?
- Yes. This settlement asks for documentation supporting your claim — a receipt, an account record, or the notice you were sent. Check the official settlement website for exactly which documents are accepted.
- Is the BioXcel Therapeutics Securities Settlement notice real, or a scam?
- Strategic Claims Services is the settlement administrator for this case. Claims are filed at bioxcelsecuritiessettlement.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the BioXcel Therapeutics Securities Settlement be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. The final approval hearing for this case is set for September 2, 2026; no payments can be issued before a settlement receives final approval.
In the news
Headlines via NewsAPI. ClaimWatch isn't affiliated with these publications.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Revance Securities Settlement
Revance Therapeutics and its executives made material misrepresentations and omissions regarding the company's relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc., allegedly violating federal securities laws. Defendants deny any wrongdoing or liability.
Not yet determinable; depends on number of valid claims submitted
Biogen Securities Litigation Settlement
Biogen Inc. investors have settled a securities litigation case for $18.9 million in cash. The settlement resolves claims related to purchases of Biogen common stock during the specified class period.
NJ Bureau of Securities Settlement with Credit Suisse
Credit Suisse allegedly violated New Jersey Securities Law by making materially false and misleading statements regarding RMBS trust certificates and engaging in fraudulent practices. On October 24, 2022, the court entered a consent order requiring Credit Suisse to pay $300 million in restitution to investors. Credit Suisse neither admitted nor denied the allegations.
Stitch Fix Securities Litigation Settlement
Stitch Fix, Inc. is settling a securities class action lawsuit without admitting wrongdoing. The Lead Plaintiffs alleged that Stitch Fix issued misleading statements about its business, and shareholders who purchased the stock during the class period suffered damages as a result.